Identification of Allosteric GCase Correctors Using Revenir™ for the Treatment of GBA1-Parkinson’s Disease
Objective: To identify novel non-inhibitory allosteric correctors of GCase using Congruence Therapeutic’s in silico proprietary drug discovery engine, Revenir™ Background: GBA1 encoding for glucocerebrosidase (GCase)…In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease
Objective: Recent experimental evidence suggests a potential interaction between dopamine D2 receptors (D2R) and N-type Ca2+ channels, impacting the firing patterns of Subthalamic neuronal (STN)…Comparative-effectiveness of Foscarbidopa/foslevodopa (LDp/CDp) versus Oral Therapies in Advanced Parkinson’s Disease: A Propensity Matched Study
Objective: To assess long-term effectiveness outcomes in people with advanced Parkinson’s Disease (aPD) on LDp/CDp versus those on oral PD therapies (standard of care, SoC).…The Purely Thermodynamic Anti-prionic Mode of Action for the Treatment of Parkinson’s Disease and other Neurodegenerative Diseases
Objective: Demonstration of the anti-prionic MoA for α-synuclein in vitro, PoC in vivo, as well as ex vivo. Background: Neurodegenerative protein-misfolding diseases, like Alzheimer’s (AD)…Deep brain stimulation contact selection using Neurophysiology and Artificial intelligence
Objective: To develop a machine learning (ML) algorithm capable of predicting the optimal deep brain stimulation (DBS) contact based on neurophysiology. Background: DBS is an…Multicenter study of efficacy and safety of subcutaneous foslevodopa/foscarbidopa treatment initiation or switch from LD/CD intestinal gel
Objective: To describe a series of patients under treatment with subcutaneous foslevodopa/foscarbidopa, either as initiation therapy or after switching from intestinal levodopa/carbidopa. Background: Treatment with…Studying digenic Parkinson’s disease in a stem cell model carrying mutant p.N409S in the GBA1 gene and the homozygous deletion of exon 3 PARK2
Objective: We aim to study the combined effect of the GBA1 p.N409S mutation and a complete loss of Parkin based on a patient-based stem cell…iPLA2β controls ER-mitochondria tethering and Ca2+ transfer in Parkinson’s disease
Objective: In this study, we aimed to investigate whether Parkinson's disease (PD) associated calcium-independent phospholipase A2β (iPLA2β) regulates the integrity and functions of endoplasmic reticulum…The role of LRRK2 in regulating microglial activity in Parkinson’s disease
Objective: To investigate the effects of pathogenic LRRK2 mutations on lysosomal function and phagocytic activity of microglia. Background: The LRRK2 G2019S mutation is one of…The functional and lipidome signature of GBA1 mutant dopaminergic neurons
Objective: The work presented here aims to link the lipidome changes leading to functional defects, and eventual cell death, in GBA1 mutant dopaminergic neurons derived…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.